BFM
TVRD

Boothbay Fund Management’s Tvardi Therapeutics TVRD Stock Holding History

Boothbay Fund Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,189
Closed -$787K – 2480
2025
Q3 		$787K Buy
+20,189
New +$575K 0.01% 934
2021
Q2 		– Sell
-1,708
Closed -$1.33M – 2171
2021
Q1 		$1.33M Buy
1,708
+857
+101% +$587K 0.05% 474
2020
Q4 		$463K Hold
851
– – 0.02% 780
2020
Q3 		$390K Hold
851
– – 0.02% 732
2020
Q2 		$524K Sell
851
-874
-51% -$483K 0.04% 568
2020
Q1 		$820K Buy
1,725
+614
+55% +$334K 0.07% 345
2019
Q4 		$644K Buy
1,111
+124
+13% +$87K 0.06% 427
2019
Q3 		$650K Sell
987
-998
-50% -$830K 0.06% 404
2019
Q2 		$1.54M Buy
1,985
+1,520
+327% +$1.07M 0.14% 183
2019
Q1 		$328K Buy
+465
New +$278K 0.03% 484
2018
Q3 		– Sell
-611
Closed -$421K – 970
2018
Q2 		$421K Buy
+611
New +$311K 0.04% 384

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Boothbay Fund Management's TVRD Position: Q4 2025 in Review

Boothbay Fund Management sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 20,189 shares — an estimated $787K sold.

Boothbay Fund Management first reported a position in TVRD in Q2 2018 and held it in 11 quarters. The position peaked at $1.54M in Q2 2019. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

  • Boothbay Fund Management reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 20,189 Tvardi Therapeutics shares in Q4 2025, an estimated $787K.
  • Boothbay Fund Management first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 11 quarters.
  • Boothbay Fund Management's Tvardi Therapeutics position peaked at $1.54M in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.